The skeleton, joints, and skeletal and cardiac muscles

Physiological Basis of Aging and Geriatrics, Fourth Edition

Volumn , Issue , 2007, Pages 329-344

  Timiras, Paola S ^a   Navazio, Franco M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84555184150     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Fedarko NS, Shapiro JR. Physiologic changes in soft tissue and bone as a function of age. In: Rosenthal RA, Zenilman ME, Katlic MR, eds. Principles and Practice of Geriatric Surgery. New York: Springer, 2001: 850-866.
2. Canalis E, ed. Skeletal Growth Factors. Philadelphia: Lippincott Williams and Wilkins, 2000.
3. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289(5484): 1501-1504.
4. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289(5484): 1504-1508.
5. Scott JE. Extracellular matrix, supramolecular organization and shape. J Anat 1995; 187(pt 2): 259-269.
6. Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 2002; 30(1): 5-7.
7. Gilsanz V, Gibbens DT, Carlson M, et al. Peak trabecular vertebral density: a comparison of adolescent and adult females. Calcif Tissue Int 1988; 43(4): 260-262.
8. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354(21): 2250-2261.
9. Wang XF, Duan Y, Beck TJ, et al. Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone 2005; 36(6): 978-986.
10. Nieves JW, Formica C, Ruffing J, et al. Males have larger skeletal size and bone mass than females, despite comparable body size. J Bone Miner Res 2005; 20(3): 529-535.
11. Currey JD. Bones: Structure and Mechanics. Princeton University Press, 2002.
12. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990; 87(18): 7260-7264.
13. Bruzzaniti A, Baron R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord 2006; 7(1-2): 123-129.
14. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22(4): 549-543.
15. Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-a (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001; 276(1): 563-568.
16. Teitelbaum SL. Osteoclasts and integrins. Ann NYAcad Sci 2006; 1068; 95-99.
17. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289(5484): 1508-1514.
18. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001; 7(8): 613-635.
19. Sato M, Grese TA, Dodge JA, et al. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem 1999; 42(1): 1-24.
20. Smith El, Sempos CT, Purvis RW. Bone mass and strength decline with age. In: Smith EL, Serfass RC, eds. Exercise and Aging, The scientific Basis. New Jersey: Enslow Publishers, 1981.
21. Rubin J, Rubin C, Jacobs CR. Molecular pathways mediating mechanical signaling in bone. Gene 2006; 367: 1-16.
22. Tepperman BL, Soper BD, Chang Q. Effect of protein kinase C activation on intracellular Ca2+ signaling and integrity of intestinal epithelial cells. Eur J Pharmacol 2005; 518(1): 1-9.
23. Anghileri LJ, Tuffet-Anghileri AM. The Role of Calcium in Biological Systems. Boca Raton: CRC Press, 1982.
24. Grynpas MD, Hancock RG, Greenwood C, et al. The effects of diet, age and sex on the mineral content of primate bones. Calcif Tissue Int 1993; 52(5): 399-405.
25. Espallargues M, Sampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int 2001; 12(10): 811-822.
26. Felson DT, Zhang Y, Hannan MT, et al. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993; 8(5): 567-573.
27. Papakitsou EF, Margioris AN, Dretakis KE, et al. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women. Maturitas 2004; 47(3): 185-193.
28. Bakhireva LN, Barret-Connor E, Kritz-Silverstein D, et al. Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 2004; 26(5): 436-442.
29. Cifuentes M, Riedt CS, Brolin RE, et al. Weight loss and calcium intake influence calcium absorption in overweight postmenopausal women. Am J Clin Nutr 2004; 80(1): 123-130.
30. Green span FS, Forsham PH. Basic Clinical Endocrinology. Los Altos: Lange Medical Publications, 1983.
31. Flicker L, Lichtenstein M, Colman P, et al. The effect of aging on intact PTH and bone density in women. J Am Geriatr Soc 1992; 40(11): 1135-1138.
32. Onyia JE, Bidwell J, Herring J, et al. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 1995; 17(5): 479-484.
33. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis and parathyroid hormone. J Clin Invest 1999; 104(4): 439-446.
34. Tinetti ME, Doucette JT, Claus EB. The contribution of predisposing and situational factors to serious fall injuries. J Am Geriatr Soc 1995; 43(11): 1207-1213.
35. Rakopoulos M, Ikegame M, Findlay DM, et al. Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone 1995; 17(5): 447-453.
36. Sambrook PN. Glucocorticoid osteoporosis. Curr Pharm Des 2002; 8(21): 1877-1883.
37. Rodan GA. Use of growth factors for osteoporotic therapy. In. Canalis E, ed. Skeletal Growth Factors. Philadelphia: Lippincott Williams and Wilkins, 2000.
38. Satariano WA. Epidemiology of aging: an ecological approach. Boston: Jones and Bartlett Publishers, 2006.
39. Richmond JH, Koval KJ, Zuckerman JD. Orthopedic Injuries. In: Rosenthal RA, Zenilman ME, Katlic MR, eds. Principles and Practice of Geriatric Surgery. New York: Springer-Verlag, 2001: 885-899.
40. Licata AA. Bisphosphonate therapy. Am J Med Sci 1997; 313(1): 17-22.
41. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonateinduced osteopetrosis. N Engl J Med 2003; 349(5): 457-463.
42. Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med 1991; 325(23): 1597-1600.
43. Wright V. Diseases of the joints. In: Pathy MSJ, ed. Practice of Geriatric Medicin. Vol 1. New York: Wiley and Sons, 1998: 1133-1164.
44. Roth RD. Joint diseases associated with aging. Clin Podiatr Med Surg 1993; 10(1): 137-159.
45. DeGroot J, Verzijl N, Wenting-Van Wijk MJ, et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum 2001; 44(11): 2562-2571.
46. Armstrong CG, Gardner DL. Thickness and distribution of human femoral head articular cartilage. Changes with age. Ann Rheum Dis 1977; 36(5): 407-412.
47. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing 1997; 26(1): 15-19.
48. Riley PO, DellaCroce U, Kerrigan DC. Effect of age on lower extremity joint moment contributions to gait speed. Gait Posture 2001; 14(3): 264-270.
49. Siegel KL, Kepple TM, Stanhope SJ. Using induced accelerations to understand knee stability during gait of individuals with muscle weakness. Gait Posture 2006; 23(4): 435-440.
50. Lark SD, Buckley JG, Jones DA, et al. Knee and ankle range of motion during stepping down in elderly compared to young men. Eur J Appl Physiol 2004; 91(2-3): 287-295.
51. Navazio F. Treatment of degenerative arthritis of the knee. Clin Ter 2003; 154(6): 445-446.
52. Woodhouse KW, Wynne H. The pharmacokinetics of nonsteroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet 1987; 12(2): 111-122.
53. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43(1): 4-13.
54. Green GA. Understanding NSAIDS: from aspirin to COX-2. Clin Cornerstone 2001; 3(5): 50-60.
55. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340(24): 1888-1899.
56. Jick H, Kaye JA, Russmann S, et al. Nonsteroidal anti-inflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy 2006; 26(10): 1379-1387.
57. McAlindon T, Formica M, LaValley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results for an internet-based randomized double-blind controlled trial. Am J Med 2004; 117(9): 643-649.
58. Committee on the use of Complementary and Alternative medicine by the American Public institute of Medicine. Complementary and Alternative Medicine in the USA. Washington DC: National Academic Press, 2005.
59. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001; 357(9252): 251-256.
60. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52(3): 779-786.
61. Levy RN, DiGiovanni J, Cohen B. Joint replacement in the elderly patient. In: Rosenthal RA, Zenilman ME, Katlic MR, eds. Principles and Practice of Geriatric Surgery. New York: Springer, 2001: 900-922.
62. McAlindon TE, Jacques P, Zhang Y, et al. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 1996; 39(4): 648-656.
63. McCarter RJ. Differential aging among skeletal muscles. In: Mascoro EJ, Austad SN, eds. The Handbook of The Biology of Aging. 6th ed. New York: Elsevier, 2006: 470-497.
64. Peason MB, Bassey EJ, Bendall MJ. Muscle strength and anthropometric indices in elderly men and women. Age Ageing 1985; 14(1): 49-54.
65. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1998; 338(13): 919-920.
66. RichMW. Heart Failure in older adults. Med Clin North Am 2006; 90(5): 863-885.
67. Svanborg A. Age-related changes in cardiac physiology. Can they be postponed or treated by drugs? Drugs Aging 1997; 10(6): 463-472.
68. Yamaji K, Fujimoto S, Ikeda Y, et al. Apoptotic myocardial cell death in the setting of arrhythmogenic right ventricular cardiomyopathy. Acta Cardiol 2005; 60(5): 465-470.
69. Communal C, Colucci WS. The control of cardiomyocyte apoptosis via the beta-adrenergic signaling pathways. Arch Mal Coeur Vaiss 2005; 98(3): 236-241.
70. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336(16): 1131-1141.
71. Van Empel VP, De Windt LJ. Human heart failure: our current status of knowledge. Cardiovasc Res 2003; 57(2): 294-297.
72. Lakatta EG, Gerstenblith G, Weisfeldt M. The Aging heart, structure, function and disease. In: Braunwald E, ed. Textbook of Cardiovascular Medicine. 5th ed. Philadelphia: W.B. Saunders, 1996: 1687-1689.
73. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001; 33(4): 655-670.
74. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation 2006; 113(24): e858-e862.
75. Barinaga M. Tracking down mutations that can stop the heart. Science 1998; 281(5373): 32-34.
76. Crabtree GR. Calcium, calcineurin, and the control of transcription. J Biol Chem 2001; 276(4): 2313-2316.
77. Towbin JA. Inflammatory cardiomyopathy: there is a specific matrix destruction in the course of the disease. Ernst Schering Res Found Workshop 2006; (55): 219-250.
78. Tanaka H, Monahan KD, Seals DR. Age-Predicted maximal heart rate revisited. J Am Coll Cardiol 2001; 37(1): 153-156.
79. Avolio AP, Deng FQ, Li WQ, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985; 71(2): 202-210.
80. Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 1988; 63(6): 552-564.
81. Leri A, Franco S, Zachero A, et al. Ablation of telomerase and telomere loss leads to cardiac dilation and heart failure associated with p53 upregulation. EMBO J 2003; 22(1): 131-139.
82. Chien KR, Knowlton KU, Zhu H, et al. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 1991; 5 (15): 3037-3046.